EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: Outlook for fiscal year 2026 and update of mid-term guidance
Werte in diesem Artikel
|
EQS-Ad-hoc: SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast/Change in Forecast Werbung Werbung SCHOTT Pharma: Outlook for fiscal year 2026 and update of mid-term guidance
Today, SCHOTT Pharma issues its financial guidance for fiscal year 2026: The company expects revenue growth at constant currencies in the range of 2-5% and an EBITDA margin of around 27%. This projection deviates from current market expectations (source: Vara consensus as of December 3, 2025) of 8.2% growth at constant currencies and an EBITDA margin of 28.8%. Further, SCHOTT Pharma updates its mid-term outlook for 2027 to 2029 to a revenue CAGR of 6-8% and expects the EBITDA margin to improve over the coming years towards 30%. Preliminary results for fiscal year 2025 are in line with market expectations and will be published in a press release later today. The full set of results for fiscal 2025 will be published on December 11, 2025, at 07:00 a.m. CET. End of Inside Information
04-Dec-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | SCHOTT Pharma AG & Co. KGaA |
| Hattenbergstraße 10 | |
| 55122 Mainz | |
| Germany | |
| ISIN: | DE000A3ENQ51 |
| WKN: | A3ENQ5 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2240736 |
| End of Announcement | EQS News Service |
|
|
2240736 04-Dec-2025 CET/CEST
Ausgewählte Hebelprodukte auf SCHOTT Pharma
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf SCHOTT Pharma
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|